308 related articles for article (PubMed ID: 28886115)
1. Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
Gui B; Hsieh CL; Kantoff PW; Kibel AS; Jia L
PLoS One; 2017; 12(9):e0184166. PubMed ID: 28886115
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
Jia L; Gui B; Zheng D; Decker KF; Tinay I; Tan M; Wang X; Kibel AS
Prostate; 2017 Jun; 77(9):1000-1011. PubMed ID: 28422308
[TBL] [Abstract][Full Text] [Related]
3. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
5. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
7. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
[TBL] [Abstract][Full Text] [Related]
8. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
9. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.
Kumar B; Khaleghzadegan S; Mears B; Hatano K; Kudrolli TA; Chowdhury WH; Yeater DB; Ewing CM; Luo J; Isaacs WB; Marchionni L; Lupold SE
Oncotarget; 2016 Nov; 7(45):72593-72607. PubMed ID: 27683042
[TBL] [Abstract][Full Text] [Related]
10. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
11. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
Sun T; Wang X; He HH; Sweeney CJ; Liu SX; Brown M; Balk S; Lee GS; Kantoff PW
Oncogene; 2014 May; 33(21):2790-800. PubMed ID: 23770851
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
[TBL] [Abstract][Full Text] [Related]
13. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
[TBL] [Abstract][Full Text] [Related]
14. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
16. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
17. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
[TBL] [Abstract][Full Text] [Related]
18. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.
Guan H; You Z; Wang C; Fang F; Peng R; Mao L; Xu B; Chen M
Cancer Med; 2019 Apr; 8(4):1474-1485. PubMed ID: 30784214
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
